02315.HK
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 60.60
−5.53%Aug 27, 2026, 08:46 UTC
Biocytogen Pharmaceuticals announced its interim results for the six months ended June 30, 2026, reporting net profit of 241 million RMB, up 402.3% year-on-year, and revenue of 941 million RMB, up 51.6% year-on-year.
Aug 6, 2026, 15:40 UTC
Biocytogen expects net profit attributable to parent for the first half of 2026 to be 236.0944 million to 246.0944 million yuan, up 391.87% to 412.71% year-on-year.
Aug 5, 2026, 04:00 UTC
Biocytogen-B (2315.HK) shares rose 9.7235% on August 5, 2026, becoming the top gainer among the Hong Kong Commercial Daily*HK Tech Index constituents that day.
Source:Jul 21, 2026, 19:36 UTC
Several Chinese public funds, including E Fund, China Asset Management, Fullgoal Fund, and China Universal Fund, increased their holdings in Hong Kong-listed biotech stocks, triggering the 5% disclosure threshold for Baioct-B, 3SBio, CSPC Pharmaceutical Group, Kelun-Biotech, and H&H International Holdings.